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Pentachlorophenol (PCP) is a pesticide that was once widely used for wood preservation.
Commercial PCP contained impurities indudinghigher chlorinated dibenzo-p-dioxins (CDDs)
and chlorinated dibenzofuans (CDFs). We investigated the effects ofoccupational exposure to
PCP and its CDD and CDF contaminants on the skin, liver, porphyrin metabolism, and central
andperipheral nervous systems. In 1986weconducted amedicalsurveyof366workerswhohad
been engaged in the production ofPCP at a single plant between 1938 and 1978. The referent
group consisted of303 workers from the same plant who were not exposed to these or related
compounds. Exposure was determined from computerized personnel records. The medical sur-
veyinduded an administered questionnaire, medical recordreview, physical nation byder-
matologists, internists, and neurologists, and analysis of24-hr urine forqua ve porphyrins
among other tests. In this paperwe present the results ofanalyses ofthe general health, chlorac-
ne, andporphyrin metabolism endpoints. The generdhealth status ofPCPworkerswas similar
to unexposed workers, but 17.8% of PCP workers had evidence of current or past chloracne.
PCP workers with chloracne hadsignificandyhigher meanurinary o nofcoproporphyrins;
(117.0 vs. 90.6 pg/24 hr) than unexposed workers after controlling for potential confounders.
Workerswith chloracne who hadworkedwithboth PCP andpolychlorinatedbiphenyls had sig-
nifiicandly higher mean urinary excretions of hepta-, penta-, and coproporphyrins than unex-
posedworkers. Wecondudethatoccupational exposure to PCP isassociatedwithchloracne and
biochemicalabnormalities which maypersistyears afterexosure. Keyword. chlorinateddiben-
zo-p-dioxins, chloracne dibenofuans, occupatioial exposures, pentahiorophenol, porphyrins.
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Pentachlorophenol (PCP) is a pesticide that
was once widely used for wood preserva-
tion. Major uses included commercial wood
treatment in the lumber industry and slime
control in the pulp and paper industry. The
sodium salt ofPCP (NaPCP) was also used
in wood preservation as a sap stain control
agent. Minor uses have included various
nonindustrial applications as a herbicide,
antimicrobial, and disinfectant.
From 1984 to 1988, the U.S. EPA
issued a series of strict regulatory controls
over the manufacture, use, and disposal of
PCP (1). Commercial pentachlorophenol
had contained a variety ofimpurities indud-
ing higher chlorinated dibenzo-p-dioxins
(CDDs) and chlorinated dibenzofurans
(CDFs). One of these compounds, hexa-
chlorodibenzo-p-dioxin (HxCDD), was
found to be a carcinogen and reproductive
toxin in laboratory animals (2). Production
ofPCP in the United States ceased in 1992.
Acute poisoning by PCP in exposed
workers produces a characteristic syndrome
of hyperpyrexia caused by uncoupling of
oxidative phosphorylation (3). The chronic
effects ofexposure to PCP have been studied
in PCP production workers (4-10), PCP
formulators (11), wood treatment workers
(12,13), sprayers (11), and sawmill workers
(1416). Several studies have demonstrated
that exposure to commercial PCP can pro-
duce chloracne (4,8-10,17,18). Some stud-
ies have observed irritant effects on the eyes
and upper respiratory tract (4,16), peripher-
al sensory neuropathy (5,10), reversible
renal impairment (12), decreased bilirubin
(8,11), increased serum glutamate dehydro-
genase (GLDH) (6), increased urinary
excretion of porphyrins (10), decreased
hematocrit and white blood cell count (15),
and increased frequency of chromosome
alterations in lymphocytes (7').
In 1986, Northwestern University con-
ducted a comprehensive morbidity study
of past and present workers at a chemical
plant in southwestern Illinois who had
been engaged in the production ofPCP as
well as lower chlorinated phenols and
esters of chlorphenoxy acids. This plant
was also a major producer ofpolychlorinat-
ed biphenyls (PCBs). The purpose of this
study was to determine ifworkers who had
been engaged in the production of PCP,
chlorinated phenols, and chlorphenoxy
acid esters suffered any long-term health
effects as a result of their past exposure to
these compounds and their CDD and
CDF contaminants. The primary hypothe-
ses of this study were that exposures to
these compounds may be associated with
chloracne, liver dysfunction, disorders of
porphyrin metabolism, neurobehavioral dis-
turbances, disorders of lipid metabolism,
and peripheral neuropathy.
This paper presents the results of the
analyses of general health status, chloracne,
and porphyrin metabolism for the group of
workers who had ever been engaged in the
production of PCP ("ever PCP"). We also
present the results of analyses for the sub-
group of these workers who produced PCP
but did not produce lower chlorinated phe-
nols or esters of chlorphenoxy acids ("only
PCP"), as well as the respective subgroups of
workers with chloracne ("ever PCP, chlorac-
ne" and "only PCP, chloracne"). The results
ofanalyses for the other exposure subgroups
and effects on other organ systems will be
presented in subsequent papers.
Materials and Methods
Plant history andprocess description. The
chemical plant whose employees were exam-
ined in this study produced pentachlorophe-
nol from 1938 to 1978. In 1986, at the time
of the survey, the plant used more than 75
raw materials to produce 22 different inter-
mediate chemical products. The major raw
materials induded chlorine, phosphorus, and
benzene. Major products included lower
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chlorinated benzenes, nitrochlorobenzene,
o-nitrophenol, nitroaniline, PCI3, P2S5,
chlorine bleaches, and detergent materials.
The plant had produced lower chlorinated
phenols from 1931 to 1983, polychlorinated
biphenyls from 1936 to 1977, and esterified
2,4,5-trichlorophenoxyacetic acid (brought
in from anotherfacility) from 1960 to 1971.
Pentachlorophenol was produced by
direct chlorination ofphenol, o-chlorophe-
nol, p-chlorophenol, 2,4-dichlorophenol,
and/or 2,4,6-trichlorophenol in the pres-
ence of an aluminum catalyst. The major
changes in production between 1938 and
1978 were related to the form of the fin-
ished product. The physical forms of PCP
induded flakes from 1938 to 1963, a 40%
solution from 1938 to 1943, prills between
1963 and 1978, and blocks between 1972
and 1978. From 1938 to 1975, molten
PCP was reacted with caustic soda to pro-
duce NaPCP. The NaPCP was produced
as briquettes from 1938 to 1956 and as
pellets from 1954 to 1975.
The company began measuring levels of
CDDs in PCP produced at this plant in
1972. That year the total CDD content in a
batch ofPCPwas determined bythe compa-
ny to be 2,500 ppm. The concentrations of
CDDs and CDFs in samples of PCP pro-
ducedatthestudyplant aregiven inTable 1.
Description ofstudypopulations. The
exposed worker populations in this study
were defined as all workers who were alive
at the time ofsample selection andwho met
one of the following definitions of expo-
sure: 1) hourly production workers who
had been engaged in theproduction ofPCP
for 3 or moredays between 1938 and 1978;
2) hourly production workers who had
been engaged in the production of mono-
and dichlorophenols between 1931 and
1983; 3) hourly production workers who
had been engaged in the esterification of
2,4,5-T and 2,4-D between 1960 and
1971. Employment in these departments
was ascertained from a computerized plant
personnel records database maintained by
the company. PCP and lower chlorinated
phenols (o-chlorophenol, p-chlorophenol,
and 2,4-dichlorophenol) were produced in
physically adjacent departments from 1938
to 1978, creating opportunities for cross-
exposure. From 1969 to 1978 these depart-
ments were merged into a single adminis-
trative unit, and separation of exposure
(PCP vs. lower chlorinated phenols) was
based on job titles rather than on depart-
mental dassifications.
An internal audit of the computerized
personnel records database revealed an over-
all error rate of2.3% on occupational expo-
sure variables. An external audit revealed
that approximately 9% ofexposed workers
could be missed by relying on this database
alone. The plant medical department had
maintained a registry ofworkers who were
undergoing medical surveillance for chlorac-
ne beginning in 1970. Twenty-nine produc-
tion workers on this chloracne registry who
met the definition ofexposure were includ-
ed in the exposed group. Maintenance and
other workers who were noted to have chlo-
racne on these plant medical records, with
the exception ofworkers who were exclu-
sively engaged in the production ofPCBs or
chlorinated benzenes, were also induded as
a separate exposure subgroup. These work-
ers were included as a separate subgroup
because, before 1983, personnel records did
not specify the departmental assignments of
maintenanceworkers.
The unexposed comparison population
was defined as workers who had ever been
employed at this same plant on or after
1931, who were alive at the time ofsample
selection, and who met the following defin-
itions ofno exposure: 1) had not worked in
any ofthe exposed departments; 2) had not
worked in maintenance; 3) had not worked
in other departments with potential expo-
sure to CDDs and CDFs (PCBs, chlorinat-
ed benzenes, derivatives of2,4-dichlorophe-
nol, or the analytical laboratory); 4) did not
work in departments immediately adjacent
to chlorophenol production. A sample of
these unexposed workers was selected by
taking all active, retired, and transferred
workers together with a random sample of
terminated workers frequency-matched to
the exposed population on age and length
ofemployment.
We located 647 of the 763 eligible
exposed workers (85%), and 473 of those
located participated in the medical exami-
nation (73%). We located 445 of the 559
eligible unexposed workers (80%), and 303
ofthose located participated in the medical
examination (68%).
This paper presents the results of the
analyses ofgeneral health status, chloracne,
and porphyrin metabolism for the group of
workers who had been engaged in the pro-
duction of pentachlorophenol. Of the 473
exposed workers in this study, 366 (77%)
were engaged in the production of pen-
tachlorophenol. Seventy-three (19.9%) of
these workers had been exposed between 3
and 29 days, 76 (20.8%) between 30 and
89 days, 65 (17.8%) between 90 and 179
days, 73 (19.9%) between 180 and 364
days, and 79 (21.6%) for 365 or more days.
Sixty-five (17.8%) of these workers had
either a history of a doctor's diagnosis of
chloracne, plant medical record evidence of
chloracne, or physical examination evidence
of chloracne at the time of dermatologic
exam. Eighty-four (23.0%) of the PCP
workers had also worked in the production
of lower chlorinated phenols; 26 (7.1%)
had worked in the production of esters of
2,4-D and 2,4,5-T. In addition, 57 (15.6%)
ofthe PCP workers had worked in the pro-
duction ofpolychlorinated biphenyls, and
Table 1. Impurities intechnical pentachlorophenol
Reference
O'Malley et al. (g)b
Component NTP8(2) Goldstein et al.(57) Mean Range
Phenols
Trichloro 0.01% NS NS
Tetrachloro 3.8% 3.0% NS
Dibenzo-p-dioxins
Tetrachloro - <0.1 ppm NS
Pentachloro NS <0.1 ppm NS
Hexachloro 10.1 ppm 8 ppm 29 ppm 1-260 ppm
Heptachloro 296 ppm 520 ppm 217 ppm 23-540 ppm
Octachloro 1,386 ppm 1,380 ppm 721 ppm 15-1,880 ppm
Dibenzofurans
Tetrachloro NS <4 ppm NS
Pentachloro 1.4 ppm 40 ppm NS
Hexachloro 9.9 ppm 90 ppm 324 ppm 190-470 ppm
Heptachloro 88 ppm 400 ppm 336 ppm 80-670 ppm
Octachloro 43 ppm 260 ppm 220 ppm 130-430 ppm
Hydroxydiphenyl ethers
Heptachloro 0.11% NS NS NS
Octachloro 1.91% NS NS NS
Nonachloro 3.56% NS NS NS
Hydroxydibenzofurans
Hexachloro 0.16% NS NS NS
Heptachloro 0.47% NS NS NS
Hexachlorobenzene 50 ppm NS NS NS
NS, notspecified.
bNTP sample: industry composite oftechnical-grade pentachlorophenol prepared from material supplied bythree U.S. manufacturers.
bFor dibenzo-p-dioxins, n = 25;fordibenzofurans, n = 8.
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114 (31.1%) of the PCP workers and 40
(13.2%) ofthe unexposed workers had also
worked in the chloralkali plant with poten-
tial exposure to elemental mercury.
Measurement ofhealth outcomes. The
study protocol was reviewed and approved
by the Institutional Review Boards of the
participating institutions. Participants pro-
vided informed consent before examination,
and the investigators assured the confiden-
tialityofindividual testresults.
The health status of participants was
measured through a comprehensive medical
examination that induded a complete med-
ical and reproductive history, physical exami-
nations, electrocardiogram, spirometry, chest
X ray, quantitative sensory testing, neurobe-
havioral evaluation, and blood, urine, and
salivatests. Reported conditionswereverified
through a review ofhospital, plant medical,
and vital records. Obtainability rates for
these records were 95% for birth records of
offspring, 57% for medical records after date
offirst employment, and 50% for requested
plant medical records. The majority ofmiss-
ingplantmedical recordswereolder, inactive
files that had been archived and lost. All
available records were reviewedandcoded by
trained record review technicians. All on-site
data collection personnel, other than the
medical interviewer administering the occu-
pational andenvironmental historyquestion-
naire, were blinded to the participants' expo-
sure status. The interviewer who adminis-
tered this questionnaire was not allowed to
share any work history information with
other examiners. Editing, reduction, and
entry of all health outcome data were also
done with the research staffblinded to the
participants' exposure status.
The medical history questionnaire was
developed with the assistance of the
University of Illinois Survey Research
Laboratory and was administered in person
bytrained interviewers. Portions ofthe ques-
tionnaire were adapted from previously used
survey instruments, induding the National
Center for Health Statistics' Health
Interview Survey (19), the NIOSH Dioxin
Morbidity Study Questionnaire (20), British
Medical Research Council's Respiratory
Questionnaire (21), theMultiple Risk Factor
Intervention Trial Questionnaire (22), and
the Swedish Questionnaire 16 (23). Each
participant received a physical examination
by a trained board-certified internist, derma-
tologist, andneurologist.
The general health status ofparticipants
was determined by both self-reporting and
internists' physical examination. Participants
were asked to rate their health as excellent,
good, fair, orpoorcompared to mostpeople
their own age. Theywere also asked to recall
the number of days over the previous 12
months that they had been hospitalized,
missedwork or usual activities due to illness,
or visited a doctor's office or clinic. Self-rat-
ing of health was treated as a categorical
variable (excellent or good vs. fair or poor)
in logistic regressions. Other self-reported
general health variables were treated as
dichotomous or continuous. Internists rated
the general appearance of participants as
normal, acutelyill, orchronicallyill.
Medical history of chloracne was
defined as a positive response to the ques-
tion, "Did a doctor ever tell you that you
had chloracne, which is a type of acne
caused by chemicals?" on the medical his-
tory questionnaire. Participants were also
asked to respond to the questions, "Has
there ever been a time when your skin
seemed unusually dark for you, even
though you hadn't had excessive sun expo-
sure?" and "Have you ever been bothered
by excess hair growth?" Plant medical
record chloracne was coded as positive if
the O'Malley score (9) was 1-3 and nega-
tive ifthe scorewas 4-6.
Dermatologists were asked to rate to
what extent the participant's examination
was consistent with the diagnosis of chlo-
racne on a five-point scale (1 = very unlike-
ly to 5 = highly likely). Participants with
scores of4 or 5 were coded as positive for
chloracne on dermatologic examination.
Dermatologists were also asked to deter-
mine if participants had hyperpigmenta-
tion orhypertrichosis.
The history of porphyria was deter-
mined by asking participants, "Have you
ever been told byadoctorthatyou had por-
phyria?" Thehistoryofsymptoms suggestive
ofporphyria was determined by asking par-
ticipants, "Have you ever had a medical
condition in which you had unusual blister-
ing of sun-exposed skin combined with
dark, reddish urine?" Dermatologists were
asked to rate on a five-point scale (1 =very
unlikely to 5 = highly likely) the extent to
which the participant's dermatologic exami-
nation was consistent with a diagnosis of
porphyria cutaneatarda.
Each participant was asked to begin a
24-hr urine collection for quantitative por-
phyrins after providing a spot morning
urine on the day ofthe examination. These
samples were submitted to the Mayo Clinic
for analysis. Urinary porphobilinogen was
measured spectrophotometrically after
complexation with Erlich's reagent by a
modification ofthe method ofSchwartz et
al. (24). Quantitative porphyrins were ana-
lyzed using high performance liquid chro-
matography (25).
Data were analyzed for completeness
and accuracy atseveral stages in the datacol-
lection and analysis. On-site quality control
derks, as well as Survey Research Laboratory
supervisors, provided continuous monitor-
ing ofthe completeness and consistency of
the data collection. Participants were rein-
terviewed where discrepancies were found.
Logical consistency constraints were added
to data input screens to minimize data entry
error. Each week a 10% random sample of
entered data was checked against the origi-
nal data. If the preestablished 0.1% error
thresholdwas exceeded, all dataentered dur-
ing that week were reentered and rechecked
foraccuracy.
A subgroup of24-hr urine samples was
split into two specimens, and both speci-
mens were submitted blind to the laborato-
ry for subsequent analysis. Coefficients of
variation for urinary porphyrins were high,
especially for those porphyrins present in
only trace amounts. The coefficient ofvari-
ation for coproporphyrins was 17.38%,
uroporphyrins 41.60%, heptaporphyrins
70.56%, and pentaporphyrins 81.87%
(hexaporphyrins were not detected in any
ofthe split samples).
Data analysis. The health status ofthe
unexposed workers was compared to the
health status ofthe ever PCP workers, only
PCP workers, ever PCP workers with chlo-
racne, andonlyPCPworkerswith chloracne.
Workers were dassified as having had chlo-
racne iftheyhad achloracne score of1-3 on
plant medical records, a chloracne score of4
or 5 on dermatologic examination, or had
reported a doctor's diagnosis ofchloracne on
themedicalhistoryquestionnaire.
The statistical significance of the unad-
justed comparisons of categorical variables
was assessed using either the Fisher's Exact
test or the chi-square test. The test for trend
was used to examine the odds of selected
health outcomes with increasing days of
exposure. The statistical significance of the
unadjusted comparisons ofcontinuous vari-
ables was assessed using either Student's t-
test or nonparametric tests. Adjustment for
confounding was performed using stratifica-
tion as well as either linear ormultiplelogis-
tic regression. A priori regression models
were constructed using known risk factors
for specific outcome variables and factors
found to be significantly associated with
t-hese outcome variables in preliminary
analyses conducted on the unexposed popu-
lation. Exposure was analyzed both as a
dichotomous variable (exposed yes/no) and
as a continuous variable using days ofexpo-
sure in production of PCP. All statistical
analyses were performed using SAS software
(26). Confounding and effect modification
from other chemical exposures at the plant
on selected health outcomes was controlled
through stratification (PCBs) and regression
analysis (mercury).
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Internist's assessment of general physi-
cal appearance was treated as a dichoto-
mous variable (normal vs. acutely or chron-
ically ill) in logistic regressions. Regression
models of the general health status out-
come variables included age, sex, race,
schooling, employment status, and expo-
sure. The statistical significance of a trend
ofincreasing odds ofhaving chloracne with
increasing days of exposure (3-29, 30-89,
90-179, 180-364, and .365 days) was
assessed using the test for trend.
Comparisons of mean urinary uropor-
phyrin, coproporphyrin, and porphobilino-
gen were performed using Student's t-test
and linear regression using nontransformed
outcome variables. Comparisons of mean
urinary penta-, hexa-, and heptaporphyrins
were performed using nonparametric tests;
these variables were log transformed in the
regression models to adjust for skewness in
their distributions. Multiple linear regres-
sions of urinary porphyrins and abnormal
values of 24-hr urine porphyrins (using
Mayo Clinic normal values) were adjusted
for age, gender, race, current alcohol con-
sumption, past mercury exposure, and
serum ferritin after excluding workers who
used estrogens. The potential confounding
and/or modifying effects of PCB exposure
on urinary porphyrin excretion were con-
trolled for through stratification.
Results
Demographic characteristics. Demographic
characteristics of the exposed and unex-
posed groups are presented in Table 2. The
distributions of workers by current
employment status in each of the PCP
exposure groups were significantly different
from the distribution of the unexposed
workers. The unexposed group had a lower
percentage of retired workers and a higher
percentage ofterminated than the exposure
subgroups. Ever PCP workers were also sig-
nificantly older (58.6 vs. 51.5 years), were
more frequently male (97.0 vs. 92.4%),
had lower household income, and had
more pack-years ofsmoking (19.5 vs. 14.9
pack-years) than unexposed workers. The
only PCP workers were also significantly
older (59.7 years) and had lower household
income than unexposed workers. PCP
workers with chloracne (ever PCP, chlorac-
ne) were also significantly older (54.8
years) and had more pack-years ofsmoking
(23.6 pack-years) compared to unexposed
workers. The only PCP workers with chlo-
racne had significantly less alcohol con-
sumption (20.8 vs. 35.8 ounces/month)
than unexposed workers. There were no
significant differences between any of the
exposure groups and unexposed workers
with regard to race.
General health. After adjusting for the
effects ofage, gender, race, years ofschool-
ing, and employment status, there were no
significant differences between the unex-
posed group and any ofthe PCP exposure
subgroups with respect to self-perception
of health, self-reported hospitalizations
over the past 12 months, or self-reported
doctor/dinic visits over the past 12 months
(data not shown). Ever PCP workers were
more likely to report staying home due to
illness over the past 12 months (adjusted
OR = 1.47, p = 0.042), but there was no
significant difference in the mean number
of days they stayed at home due to illness
(ever PCP 6.6 days vs. unexposed 4.9
days). There were no significant differences
between the unexposed group and the ever
PCP, chloracne or only PCP, chloracne
subgroups with regard to these same gener-
al health indicators after adjustment. Also,
there were no significant differences, either
unadjusted or adjusted, between unexposed
and any of the PCP exposure subgroups
with regard to the internist's assessment of
their general physical appearance.
Chloracne. Sixty-five (17.8%) ofthe 366
ever PCP workers had either a history of a
doctor's diagnosis ofchloracne (42 workers),
evidence of chloracne on plant medical
records (41 workers), or evidence ofcurrent
chloracne at the time ofdermatologic exam
(14 workers). The percentage of ever PCP
workers with chloracne by medical history,
plant medical records, or dermatology exam
increased with duration of exposure (5.5%
for those who worked 3-29 days, 6.6% for
30-89 days, 15.4% for 90-179 days, 24.7%
for 180-364 days, and 35.4% for those who
worked for 1 or more years;p<0.001). There
were no significant differences in self-report-
ed hyperpigmentation or hyperpigmentation
found on dermatologic examination between
the unexposed workers andworkers in either
ofthe chloracnegroups.
Porphyrins. None ofthe workers in this
study reported a doctor's diagnosis ofpor-
phyria. There were no significant differ-
ences between any of the exposure groups
and the unexposed group with respect to
symptoms of reddish urine and blistering
skin. Three workers in the ever PCP, chlo-
racne group were found to have hypertri-
chosis on dermatologic exam compared to
one in the unexposed group (4.6% vs.
0.3%, p = 0.019). Two workers in the only
PCP, chloracne group were found to have
hypertrichosis on dermatologic examination
(6.5% vs. 0.3%; p = 0.024). These two
workers also accounted for a significantly
Table2. Demographic characteristics by exposure subgroups
Ever PCP, Only PCP,
Unexposed Ever PCP chloracne Only PCP chloracne
(n=303) (n=366) (n= 65) (n= 260) (n=31)
Characteristic No. % No. % No. % No. % No. %
Sex
Male 280 92.4 355 97.0** 63 96.9 250 96.2 30 96.8
Female 23 7.6 11 3.0 2 3.1 10 3.9 1 3.2
Race
White 255 84.2 320 87.4 56 86.2 227 87.3 28 90.3
Black 47 15.5 44 12.0 8 12.3 32 12.3 3 9.7
Other 1 0.3 2 0.6 1 1.5 1 0.4 0 0.0
Household income (thousands)
<10 12 4.0 27 7.5* 3 4.7 20 7.8# 2 6.7
10-19 53 17.5 87 24.0 9 14.1 79 30.7 6 20.0
20-29 58 19.2 81 22.4 15 23.4 49 19.1 4 13.3
30-39 88 29.0 89 24.6 25 39.1 57 22.2 13 43.3
40-49 55 18.2 43 11.9 4 6.3 29 11.3 2 6.7
.50 37 12.2 35 9.7 8 12.5 23 9.0 3 10.0
Employment status
Active 96 31.7 91 24.9' 29 44.6** 42 16.2' 11 35.5'
Transfered 10 3.3 34 9.3 7 10.8 28 10.8 5 16.1
Retired 27 8.9 127 34.7 20 30.8 89 34.2 9 29.0
Terminated 170 56.1 114 31.1 9 13.8 101 38.9 6 19.4
Age (years)
Mean 51.5 58.6' 54.8 59.71' 56.2
SD 15.0 10.5 10.9 10.3 11.5
Range 25-86 29-79 31-73 29-79 31-73
Pack-years smoked
Mean 14.9 19.5** 23.6* 18.4 17.7
SD 20.9 22.6 26.1 21.7 19.6
Current alcohol consumption (ounces/month)
Mean 35.8 30.6 30.4 30.5 20.8*
SD 60.9 54.0 45.0 57.0 35.4
Abbreviations: PCP, pentachlorophenol; SD, standard deviation.
*0.01 <p<.0.05;*0.001 <p<0.01; p<0.001.
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higher prevalence of history of excess hair
growth in the only PCP, chloracne sub-
group (6.5% vs. 0.7%;p = 0.045).
A comparison of24-hr urine porphyrins
by exposure subgroups is presented in Table
3. After excluding workers on estrogens and
adjustingforage, gender, race, current alcohol
consumption, past mercury exposure, and
serumferritin, therewerenosignificant differ-
ences between the unexposed group and the
ever PCP or only PCP groups with respect to
mean urinary excretion ofporphyrins or per-
cent abnormal excretion with either dichoto-
mous exposure or days ofexposure. Workers
in the ever PCP, chloracne group had ahigh-
er mean urinary excretion ofcoproporphyrin
(113.2 pg vs. 90.6 pg; p = 0.0002) and a
higher percentage of abnormal copropor-
phyrin excretion (67.7% vs. 44.0%;
p= 0.001) compared to unexposedworkers in
the unadjusted analyses. These differences
remained statistically significant in the adjust-
ed analyses. Ever PCP, chloracne workers also
had asignificantlyhigher mean urinaryexcre-
tion ofheptaporphyrin compared to unex-
posed workers (4.0 pgvs. 3.2 pg;p = 0.0355)
in the adjusted analysis. Workers in the only
PCP, chloracne group also had a significantly
higher urinary excretion ofcoproporphyrin
compared to unexposedworkers [117.0 pgvs.
90.6 pg in both the unadjusted (p = 0.029)
and adjusted (p = 0.004) analyses]. The two
workers in the only PCP, chloracne group
who also had hypertrichosis had mild copro-
porphyrinuria (149 pg and 136 pg/24 hr)
with normal urinary excretion of uropor-
phyrins. The percentage ofabnormal urinary
coproporphyrin excretion in the only PCP,
chlorance group was also higherthan in unex-
posed workers (61.3% vs. 44.0%), but this
difference was not statistically significant in
eitherthe unadjustedoradjustedanalyses.
Table4 presents mean, median, and per-
cent abnormal urinary excretion of por-
phyrins byPCP exposuresubgroup stratified
on PCB exposure. The eight workers in the
ever PCP, chloracne subgroup who had also
worked in the PCB department had greater
mean 24-hr urinary excretion of uropor-
phyrin (38.9 pg vs. 24.9 pg; p = 0.09), hep-
taporphyrin (7.0 pg vs. 3.2 pg; p<0.01),
pentaporphyrin (8.4 pg vs. 2.3 pg; p<0.01),
and coproporphyrin (167.3 pg vs. 90.6 pg;
p<O.OOl) than the unexposed group in mul-
tivariable analysis. The percentage ofabnor-
mal urinary excretion ofcoproporhyrins was
significantly different from unexposed work-
ers in the ever PCP, chloracne workers who
had not also worked with PCBs (63.2% vs.
44.0%). The four workers in the only PCP,
chloracne subgroup who had also worked in
the PCB department had significantly
greater 24-hr urinary excretion ofheptapor-
phyrin (5.5 pg vs. 3.2 pg; p<0.05), penta-
porphyrin (13.3 pg vs. 2.3 pg; p<0.001);
and coproporphyrins (215.3 pg vs. 90.6 pg;
Table3. Comparison of24-hr urine porphyrins by exposure subgroup,
Ever PCP, Only PCP,
Urinary Unexposed Ever PCP chloracne Only PCP chloracne
porphyrin (pg) (n=295) (n=357) (n =64) (n= 253) (n= 30)
Uroporphyrin
Mean 24.9 25.0 27.9 23.6 22.9
Median 21 21 23.5 20 21
% Abnormalb 8.8 9.0 10.9 7.5 3.3
Hepta
Mean 3.2 3.9 4.0* 3.5 3.0
Median 2 2 3 2 3
% Abnormal 1.0 2.5 3.1 1.6 0.0
Hexa
Mean 1.2 1.3 1.3 1.3 1.6
Median 1 1 1 1 1
% Abnormal 1.7 1.1 1.6 1.6 3.3
Penta
Mean 2.3 2.3 3.3 2.3 4.2
Median 1 1 2 1 2
% Abnormal 12.8 10.2 18.5 8.9 22.6
Copro
Mean 90.6 91.9 113.2** 90.9 117.0**
Median 85.5 85.5 110 82.5 114
% Abnormal 44.0 40.1 67.7** 36.8 61.3
Porphobilinogen
Mean 1.09 1.07 1.15 1.04 1.06
Median 1 1 1.1 0.95 0.9
% Abnormal 6.0 4.4 4.6 3.1 0.0
PCP, pentachlorophenol.
"All p-values adjusted for age, gender, race, current alcohol, mercury exposure, and ferritin after excluding workers who used estrogens.
Penta-, hexa-, and hepta- logtransformed; uro- and coproporphyrin and porphobilinogen nottransformed.
bAbnormal for males defined as uro>46; hepta>13; hexa >5; penta >4; copro >96. Abnormal for females defined as uro>22; hepta >9; hexa >4;
penta >3; copro >60. Abnormal porphobilinogen >2for males and females.
*0.01 <p<0.05; **p< 0.01
p<O.OOl) than the unexposed group in mul-
tivariable analysis.
Discussion
The purpose ofthis morbidity study was to
determine ifworkers who had been engaged
in the production ofPCP suffered anylong-
term health effects as a result oftheir expo-
sures to PCP and its CDD and CDF conta-
minants. The time since last exposure
ranged from 8 to more than 30 years. As
PCP has an elimination half-life of 30.2 hr
(27), these workers were unlikely to have
significant residual body burdens of PCP.
Some CDDs and CDFs, however, havelong
elimination half-lives and appreciable levels
can persist many years after exposure (28).
This study was designed to measure the
prevalence of persistent effects years after
exposure and not the incidence ofreversible
health effects during or shortly after expo-
sure. Our primary hypotheses included
those health effects that some investigators
have reported in dioxin-exposed individuals
many years after exposure, specifically chlo-
racne (4,8-10,29-38), liver dysfunction
(6,20,31,33,35,39), disorders ofporphyrin
metabolism (10,35,37,40,41), neurobehav-
ioral disturbances (35,36,42-45), disorders
of lipid metabolism (32,35,43,46,47), and
peripheral neuropathy (4,5,10,31,35,42,
48-51). The analyses in this paper focus on
general health status, chloracne, and disor-
ders ofporphyrin metabolism.
In ourstudy, 17.8% ofworkerswho had
ever been engaged in the production ofPCP
had evidence ofchloracne by medical histo-
ry, plant medical records, or dermatologic
exam. Chloracne resolved in the majority of
affected workers: only 11.3% of those who
reported a doctor's diagnosis of chloracne
still had chloracne at the time ofdermato-
logic exam. The odds ofdeveloping chlorac-
ne increasedwith duration ofexposure.
O'Malley et al. (9) reviewed the plant
medical records ofworkers who had been
engaged in the production ofPCP between
1951 and 1978 at this plant. Seven percent
of the workers had evidence of chloracne
on plant medical records, compared to
8.8% in our only PCP, chloracne group.
O'Malley et al. did not find a significant
trend between standardized incidence
ratios of chloracne and duration of expo-
sure. The differences in our results for
trend between duration of exposure and
chloracne may be due to differences in the
selection of intervals for duration of expo-
sure. We found a significant trend in the
odds of developing chloracne during the
firstyear ofexposure using time intervals of
3-29, 30-89, 90-179, 180-364, and .365
days. O'Malley et al. selected time intervals
ranging from <0.5 to .10 years.
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Table4. Comparison of24-hr urine porphyrins by PCP/PCB exposure subgroup°
EverPCP, OnlyPCP,
Ever PCP chloracne OnlyPCP chloracne
Urinary Unexposed PCB No PCB PCB No PCB PCB NoPCB PCB No PCB
porphyrin(pg) (n=295) (n=57) (n=307) (n=8) (n=56) (n=37) (n=221) (n=4) (n=26)
Uroporphyrin
Mean 24.9 28.3 24.4 38.9 26.4 23.4 23.6 29.5 21.9
Median 21 24 21 38.5 22 24 19 30.5 20
%Abnormalb 8.8 12.3 8.3 25.0 8.9 5.4 7.9 0.0 3.9
Hepta
Mean 3.2 5.4 3.6 7.0** 3.6 3.4 3.5 5.5* 2.7
Median 2 3 2 5 3 2 2 5 2
%Abnormal 1.0 7.0 1.6 12.5 1.8 2.7 1.4 0.0 0.0
Hexa
Mean 1.2 1.2 1.3 1.4 1.3 1.1 1.3 1.8 1.5
Median 1 1 1 1 1 1 1 1 1
%Abnormal 1.7 0.0 1.3 0.0 1.8 0.0 1.9 0.0 3.9
Penta
Mean 2.3 2.9 2.2 8.4** 2.6 2.8 2.2 13.3** 2.8
Median 1 1 1 2.5 1 1 1 6.5 1
%Abnormal 12.8 12.3 9.8 37.5 15.8 8.1 9.1 50.0 18.5
Copro
Mean 90.6 90.1 92.2 167.3** 105.6 92.1 90.7 215.3** 1024
Median 85.5 89 85 121 104 84 82 194.5 105
%Abnormal 44.0 42.1 39.7 100.0 63.2* 40.5 36.2 100.0 55.6
Porphobilinogen
Mean 1.09 0.9 1.1 1.05 1.16 0.9 1.07 1.0 1.07
Median 1 0.9 1 1.1 1.1 0.9 1 1 0.9
%Abnormal 6.0 3.5 4.6 0.0 5.3 2.7 3.2 0.0 0.0
Abbreviations: PCP, pentachlorophenol; PCB,polychlorinated biphenyls.
'All p-values adjusted for age, gender, race, current alcohol, mercury exposure, and ferritn after excluding workers who used estrogens.
Penta-, hexa-, and hepta- logtransformed; uro- and coproporphyrin and porphobilinogen nottransformed.
bAbnormal formales defined as uro >46; hepta >13; hexa >5; penta >4; copro>96. Abnormal forfemales defined as uro >22;hepta >9; hexa >4;
penta >3; copro >60. Abnormal porphobilinogen >2formales andfemales.
*0.01 <p!<0.05;**p<0.01.
Chloracne has also been observed in
PCP production workers at other plants
(4,8,10) and in a worker with prolonged
exposure to PCP-treated wood (18).
Technical PCP has been shown to produce
chloracne in a rabbit ear model, whereas
pure PCP does not (52).
Our PCP workers with chloracne had
significantly elevated mean urinary excre-
tions of coproporphyrin compared to the
unexposed workers after control for poten-
tial confounders. There were no significant
differences in the urinary excretion of uro-
porphyrins, and none ofparticipants had a
history of porphyria cutanea tarda. The
pattern of porphyrin excretion in our
workers with chloracne is consistent with
subdinical, low-grade coproporphyrinuria.
Studies of porphyrin metabolism in
TCDD-exposed individuals have yielded
conflicting results. In the two plants where
workers had clinical porphyria (35,3X),
hexachlorobenzene may have been a con-
founding exposure (53). Calvert et al. (54)
did not find significant associations between
serum levels of TCDD and porphyria
cutanea tarda, uroporphyrinuria, or copro-
porphyrinuria in a cohort ofworkers who
had been exposed to chemicals contaminat-
ed with TCDD more than 15 years earlier.
Residents ofSeveso have been found to have
subdinical coproporphyrinuria compared to
controls (41). Theonlydocumented cases of
porphyria cutanea tarda among Seveso resi-
dents occurred in a family with congenital
uroporphorinogen decarboxylase (UROD)
deficiency (40).
Studies of PCP-exposed workers have
also yielded conflicting results. Baxter (8)
found no abnormalities in the urinary
excretion of coproporphyrin, uropor-
phyrin, and &-aminolevulinic acid (ALA)
among workers engaged in the production
ofPCP at a plant in the United Kingdom.
Cheng et al. (10) found higher excretion of
urinary porphyrins and ALA among
Chinese workers engaged in the production
ofPCP than in controls. At the plant stud-
ied by Cheng et al., PCP was produced
through a series of steps involving hexa-
chlorocyclohexane, trichlorobenzene, and
hydroxylation ofhexachlorobenzene. Pines
et al. (55) found higher mean urinary
excretion of coproporphyrin and ALA in
workers employed in wood processing and
furniture manufacture compared to con-
trols. Workers in this pilot study, however,
were exposed not only to technical PCP
but also to solvents used in wood finishing.
Coproporphyrinuria has also been observed
in workers with high serum concentrations
ofPCBs (56).
Animal studies are consistent with the
induction of porphyrinuria by exposure to
contaminants present in technical PCP.
Goldstein et al. (52) compared the por-
phyrinogenic effect of technical (contami-
nated with CDDs and CDFs) versus pure
PCP in female rats. Rats fed 500 ppm of
technical PCP for 8 months had significant
elevations in urinary excretion ofcopropor-
phyrin, uroporphyrin, and ALA compared
to controls, whereas pure PCP was not por-
phyrinogenic. Technical PCP, however,
did not increase the activity ofALA syn-
thetase in this study, although dioxins such
as TCDD are believed to exert their por-
phyrinogenic effect through induction of
ALA synthetase as well as inhibition of
UROD (58).
In our study, urinary porphyrin excre-
tion was highest among the subgroups of
workers with chloracne who had worked
with both PCP and PCBs. Results ofrecent
animal studies suggest a possible synergistic
interaction between certain PCB congeners
and TCDD in producinghepatic porphyrin
accumulation. Van Birgelen et al. (59)
observed an 800-fold increase in hepatic
porphyrin accumulation in female Sprague-
Dawley rats that were coadministered PCB
153 andTCDD in a 13-weekfeedingstudy.
Van Birgelen et al. hypothesize that the syn-
ergistic interaction observed in their animal
studies may be due to the combined effects
of Ah-receptor-mediated induction of
CYP1A2, which may play a role in the oxi-
dation of uroporphyrinogen III to uropor-
phyrin III, together with possible induction
ofALA synthetase. These animal data are
consistent with our observation ofelevated
urinary porphyrin excretion among workers
with chloracne who had worked with both
PCP and PCBs. The contaminants present
in the technical PCP produced at the study
plant are listed in Table 1. Potential por-
phyrinogens include the chlorinated diben-
zodioxins and chlorinated dibenzofurans.
An alternative explanation may be contami-
nation of technical PCP with hexa-
chlorobenzene. Although hexachloroben-
zene was not measured in the PCP pro-
ducedat this plant, an industrycomposite of
technical-grade pentachlorophenol prepared
from material supplied by three U.S. manu-
facturers contained low concentrations of
hexachlorobenzene (50 ppm), which is a
known porphyrinogen in humans (2). We
were unable to test for statistical interaction
between PCP and PCB exposure on urinary
porphyrin excretion in ourstudybecausewe
did not have a separate study group exposed
to PCBs alone.
Mean porphyrin levels in our unex-
posed group were higher than those of
many, but not all, previous studies (60).
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Differences among these studies may be
due to variations in laboratory procedures,
a possibility supported by the high coeffi-
cients ofvariation ofour porphyrin assays.
An alternative explanation is exposure to
other porphorinogens, such as alcohol or
other chemicals at the plant. Both ofthese
factors would tend to bias the results
toward the null hypothesis.
The major limitations of this study are
reliance on historical personnel records and
chloracne as measures ofexposure, potential
confounding from other chemical exposures,
use ofprevalence rather than incidence as our
predominant measure of disease frequency,
and low power in the subgroup analyses.
Although direct bioassay of PCDDs and
PCDFs in adipose tissue or serum is the most
reliable index ofexposure, this was not tech-
nically or logistically feasible in the present
study. Fingerhut et al. (61) found that serum
levels of2,3,7,8-TCDD were related to dura-
tion of employment in workers engaged in
the production of2,4,5-trichlorophenol and
2,4,5-trichlorophenoxyacetic acid. Neuberger
et al. (62) found higher serum levels of
2,3,7,8-TCDD in production workers with
chloracne compared to unexposed referents,
whereas Beck et al. (63) found little correla-
tion between adipose PCDD or PCDF con-
centrations and incidence of chloracne in
exposed workers. Chloracne maybe a marker
of both exposure and susceptibility in
exposedworkers.
A limitation inherent in the cross-sec-
tional design is the use ofprevalence rather
than incidence as a measure of disease fre-
quency. Ifexposure affects survival or ability
to participate in the examination due to ill-
ness, then this could bias the results toward
the null hypothesis. The long lag times
between last exposure and time of medical
examination limit our ability to study past
events. Finally, the small numbers of indi-
viduals in our highest exposure groups (ever
and only PCP, chloracne), limit our ability
to detect significant differences due to low
study power, and negative results should be
interpreted with a consideration of the
potential for beta error.
Despite these limitations, this is the
largest morbidity study ofpentachlorophe-
nol production workers conducted to date
and provides important information on the
health status ofworkers with past exposure
to PCP and its CDD and CDF contami-
nants. Overall, the general health status of
these PCP-exposed workers was similar to
unexposed workers. The major clinical
effect we observed in PCP-exposed workers
was chloracne. The other finding we
believe is consistent with current knowl-
edge of the effects of exposure to CDDs
and CDFs is elevation in urinary excretion
of coproporphyrins in persons with chlo-
racne. The high urinary excretion of uro-,
hepta-, penta-, and coproporphyrins
among the subgroup ofworkers with chlo-
racne who had worked with both PCP and
PCBs suggests a possible interaction
between compounds present in technical
PCP and PCBs on porphyrin metabolism.
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